Posts tagged Cantor


Dynavax Technologies Corporation (DVAX) Gains a Cantor Bull on Back of Compelling HBV Opportunity

Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.

Read more

Snap Inc (SNAP) Gets a Price Target Boost on Meaningful Upside Potential for Monetization Per Minute

Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.

Read more

Cantor Asserts That Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Loan Amendments Get Rid of Meaningful Overhang on Stock

Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.

Read more

Supernus Pharmaceuticals Inc (SUPN) Investors Are Scared Off by Elimination of Low SPN-810 Dose; Cantor Makes a Bullish Case

Supernus investors are running for the hills, but analyst sees elimination of 18 mg dose as a good move.

Read more

Another Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Divestiture? Cantor Says Women’s Health Franchise Sale Could Drive Share Appreciation

Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.

Read more

Cantor Spotlights Meaningful Opportunity for Nabriva Therapeutics plc – Ordinary Shares (NBRV) in CABP as Stock Goes Through the Roof

Analyst believes impressive Phase 3 data read-out bolsters expectations for lefamulin’s peak sales potential.

Read more

Array Biopharma Inc’s (ARRY) BRAF-Mutant Melanoma Combo Treatment Gets a PDUFA Date; Cantor Chimes In

Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.

Read more

Health Insurance Innovations Inc Shares Face the Heat; Cantor Finds Weakness Unfounded

Analyst dismisses negative publicity haunting HIIQ as unjustified extrapolation from past settlements.

Read more

Cantor Now Sees Bigger Market Opportunity for Array Biopharma Inc’s (ARRY) Binimetinib/Encorafenib Following ESMO Presentation

Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.

Read more

Cantor Believes Teva Pharmaceutical Industries Ltr (ADR) New CEO Will Unlock Value for Shares

Analyst Louise Chen cheers that new Danish CEO means “good news” for Tesla investors.

Read more